Trial Profile

A Phase I/II Study of Ado-Trastuzumab Emtansine (T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABT 737 (Primary) ; Trastuzumab emtansine (Primary)
Indications Breast cancer
Focus Adverse reactions

Most Recent Events

30 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to recruitment.
19 Mar 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com